SE9300300D0 - A NOVEL ANTICOAGULANT ENTITY, ANTIBODIES REACTING SPECIFICALLY WITH THE ENTITY, AND DIAGNOSTIC AND THERAPEUTIC USED OF THE ENTITY - Google Patents
A NOVEL ANTICOAGULANT ENTITY, ANTIBODIES REACTING SPECIFICALLY WITH THE ENTITY, AND DIAGNOSTIC AND THERAPEUTIC USED OF THE ENTITYInfo
- Publication number
- SE9300300D0 SE9300300D0 SE9300300A SE9300300A SE9300300D0 SE 9300300 D0 SE9300300 D0 SE 9300300D0 SE 9300300 A SE9300300 A SE 9300300A SE 9300300 A SE9300300 A SE 9300300A SE 9300300 D0 SE9300300 D0 SE 9300300D0
- Authority
- SE
- Sweden
- Prior art keywords
- entity
- diagnostic
- reacting specifically
- antibodies reacting
- factor
- Prior art date
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
1. The method of identifying an individual's propensity to develop thrombosis as a result of inherited APC immunity, caused by (a) genetic mutation(s). Characterized in that: The presence of Factor V gene mutations is detected in sample cells of a given individual. The mutations are located in one or many fragments and/or in the nucleic acid sequence in the Factor V gene. They cause the expression of the mutated Factor V/Va molecule, which is connected to the presence of the APC immunity, i.e. to the propensity to develop thrombosis.
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9300300A SE9300300D0 (en) | 1993-01-29 | 1993-01-29 | A NOVEL ANTICOAGULANT ENTITY, ANTIBODIES REACTING SPECIFICALLY WITH THE ENTITY, AND DIAGNOSTIC AND THERAPEUTIC USED OF THE ENTITY |
HU9502190A HUT72191A (en) | 1993-01-29 | 1994-01-28 | Novel anticoagulant cofactor activity |
ES94905908T ES2119165T5 (en) | 1993-01-29 | 1994-01-28 | NEW ANTICOAGULATING COFACTOR ACTIVITY. |
PCT/SE1994/000070 WO1994017415A1 (en) | 1993-01-29 | 1994-01-28 | Novel anticoagulant cofactor activity |
CZ951849A CZ184995A3 (en) | 1993-01-29 | 1994-01-28 | Novel anticoagulative cofactor activity |
NZ261190A NZ261190A (en) | 1993-01-29 | 1994-01-28 | Assaying for functional activity of a blood coagulation component involved in the protein c anticoagulant system (protein c, activated protein c, protein s or anticoagulant factor v) |
DE69411898T DE69411898T3 (en) | 1993-01-29 | 1994-01-28 | NEW ANTI-COAGULANT COFACTOR ACTIVITY |
AU59827/94A AU690535B2 (en) | 1993-01-29 | 1994-01-28 | Novel anticoagulant cofactor activity |
US08/500,917 US7169572B1 (en) | 1993-01-29 | 1994-01-28 | Assays for determining anticoagulant cofactor activity |
PL34254994A PL181638B1 (en) | 1993-01-29 | 1994-01-28 | Method of determining thrombosis susceptibility of patient's organism |
AT94905908T ATE168781T1 (en) | 1993-01-29 | 1994-01-28 | NEW ANTICOAGULANT COFACTOR ACTIVITY |
PL94310050A PL181102B1 (en) | 1993-01-29 | 1994-01-28 | Novel activity of anticoagulant cofactor |
CA002154080A CA2154080C (en) | 1993-01-29 | 1994-01-28 | Novel anticoagulant cofactor activity |
EP94905908A EP0690991B2 (en) | 1993-01-29 | 1994-01-28 | Novel anticoagulant cofactor activity |
BR9406223A BR9406223A (en) | 1993-01-29 | 1994-01-28 | Method for determining the functional activity of a blood coagulation component in a sample packaged plasma plasma deficient in factor v anticoagulant activity as a cofactor for use of the antibody preparation prepared from protein s prepared from |
DK94905908T DK0690991T4 (en) | 1993-01-29 | 1994-01-28 | New anticoagulant cofactor activity |
JP6516938A JPH08506181A (en) | 1993-01-29 | 1994-01-28 | Novel anticoagulant cofactor activity |
FI953565A FI953565A0 (en) | 1993-01-29 | 1995-07-26 | New anticoagulant cofactor activity |
GR980401874T GR3027697T3 (en) | 1993-01-29 | 1998-08-20 | Novel anticoagulant cofactor activity |
US11/560,502 US20070212743A1 (en) | 1993-01-29 | 2006-11-16 | Assays for Determining Anticoagulant Cofactor Activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9300300A SE9300300D0 (en) | 1993-01-29 | 1993-01-29 | A NOVEL ANTICOAGULANT ENTITY, ANTIBODIES REACTING SPECIFICALLY WITH THE ENTITY, AND DIAGNOSTIC AND THERAPEUTIC USED OF THE ENTITY |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9300300D0 true SE9300300D0 (en) | 1993-01-29 |
Family
ID=20388725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9300300A SE9300300D0 (en) | 1993-01-29 | 1993-01-29 | A NOVEL ANTICOAGULANT ENTITY, ANTIBODIES REACTING SPECIFICALLY WITH THE ENTITY, AND DIAGNOSTIC AND THERAPEUTIC USED OF THE ENTITY |
Country Status (2)
Country | Link |
---|---|
PL (1) | PL181638B1 (en) |
SE (1) | SE9300300D0 (en) |
-
1993
- 1993-01-29 SE SE9300300A patent/SE9300300D0/en unknown
-
1994
- 1994-01-28 PL PL34254994A patent/PL181638B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL181638B1 (en) | 2001-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bajaj et al. | Simultaneous purification of bovine prothrombin and factor X: Activation of prothrombin by trypsin-activated factor X | |
Brunelle et al. | Missing contact probing of DNA-protein interactions. | |
Solomon et al. | Light chain-associated amyloid deposits comprised of a novel κ constant domain | |
Azen | Genetic protein polymrophisms in human saliva: An interpretive review | |
FI954855A (en) | Method for screening for the presence of a genetic defect in protein C activated by thrombosis and / or a poor anticoagulant response | |
ATE90792T1 (en) | DIAGNOSTIC METHODS FOR DETECTING LYMPHOMA IN HUMANS. | |
ATE184052T1 (en) | GDF-1 AND UOG1 PROTEINS | |
IT1155089B (en) | FRAGMENTS OF ADN MARKED IN CORRESPONDENCE OF AT LEAST ONE OF THEIR EXTREMITIES THROUGH RECOGNIZABLE MODIFIED RIBONUCLEOTIDES MEDINATED RELATED MOLECULES AND PROCEDURE FOR CARRYING OUT AN ANALYSIS OF SUCH FRAGMENTS | |
O'Sullivan et al. | Identification of salivary basic proline-rich proteins as receptors for Candida albicans adhesion | |
DE59610519D1 (en) | Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli | |
ATE163676T1 (en) | MOLECULAR CLONES OF HIV-1 AND THEIR USE | |
Francus et al. | An IgG2a-producing variant of an IgG2b-producing mouse myeloma cell line. Structural studies on the Fc region of parent and variant heavy chains | |
Argaman et al. | Antigenic properties of mycoplasma organisms and membranes | |
DE69840895D1 (en) | MONOSPECIFIC ANTIBODIES TO FIBRINOGENS AND FIBRINOPEPTIDES B | |
SE9300300D0 (en) | A NOVEL ANTICOAGULANT ENTITY, ANTIBODIES REACTING SPECIFICALLY WITH THE ENTITY, AND DIAGNOSTIC AND THERAPEUTIC USED OF THE ENTITY | |
BR9713450A (en) | Mammalian chemokines | |
Stephenson et al. | Typing of Aeromonas species by polyacrylamide-gel electrophoresis of radiolabelled cell proteins | |
EP0292663A1 (en) | A method for producing vitronectin | |
ATE346919T1 (en) | Epididymis-SPECIFIC RECEPTOR PROTEIN AND USE THEREOF | |
Azen et al. | Alleles at the PRB3 locus coding for a disulfide-bonded human salivary proline-rich glycoprotein (Gl 8) and a null in an Ashkenazi Jew. | |
HUP9801330A2 (en) | Novel pka-binding proteins and uses thereof | |
ATE548468T1 (en) | FOR BACTERIAL ANTIGENS SPECIFIC NUCLEIC ACID MOLECULES AND THEIR USE | |
BR9815519A (en) | Isolated nucleic acid fragment, chimeric gene, transformed host cell, method of altering the level of expression of a plant glycogenin, method of obtaining an isolated nucleic acid fragment and product | |
ATE109509T1 (en) | ANTICOAGULATORY PROTEIN PP4-X, ITS PRODUCTION AND USE. | |
DK145988D0 (en) | GENETIC MANUFACTURED 140 KD ANTIGEN OF PLASMODIUM FALCIPARUM AND ITS USE |